Related references
Note: Only part of the references are listed.Characterization of novel conformation-selective alpha-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease
Michael X. Henderson et al.
NEUROBIOLOGY OF DISEASE (2020)
The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson's disease, multiple system atrophy and dementia with Lewy bodies
Anke Van der Perren et al.
ACTA NEUROPATHOLOGICA (2020)
How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology
Senthil T. Kumar et al.
NEUROBIOLOGY OF DISEASE (2020)
Immunotherapy Targeting Neurodegenerative Proteinopathies: α-Synucleinopathies and Tauopathies
Junghwan Shin et al.
JOURNAL OF MOVEMENT DISORDERS (2020)
Clinical and neuropathological differences between Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies - current issues and future directions
Lauren Walker et al.
JOURNAL OF NEUROCHEMISTRY (2019)
Naturally occurring antibodies target Parkinson disease pathology
Heather Wood
NATURE REVIEWS NEUROLOGY (2019)
Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer's disease
James A. R. Nicoll et al.
BRAIN (2019)
Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes
Sarah H. Shahmoradian et al.
NATURE NEUROSCIENCE (2019)
Dementia with Lewy bodies: an update and outlook
Tiago Fleming Outeiro et al.
MOLECULAR NEURODEGENERATION (2019)
Naturally occurring antibodies isolated from PD patients inhibit synuclein seeding in vitro and recognize Lewy pathology
Xinyi Li et al.
ACTA NEUROPATHOLOGICA (2019)
Multiple System Atrophy: An Oligodendroglioneural Synucleinopathy
Kurt A. Jellinger
JOURNAL OF ALZHEIMERS DISEASE (2018)
Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies
Chao Peng et al.
NATURE (2018)
Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy
Martin Kallab et al.
FRONTIERS IN NEUROSCIENCE (2018)
Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
E. Ray Dorsey et al.
LANCET NEUROLOGY (2018)
First-in-human assessment of PRX002, an anti--synuclein monoclonal antibody, in healthy volunteers
Dale B. Schenk et al.
MOVEMENT DISORDERS (2017)
Vaccination strategies in tauopathies and synucleinopathies
Anne K. Braczynski et al.
JOURNAL OF NEUROCHEMISTRY (2017)
A retrospective analysis of the Alzheimer's disease vaccine progress - The critical need for new development strategies
Dante J. Marciani
JOURNAL OF NEUROCHEMISTRY (2016)
Structural and functional properties of prefibrillar α-synuclein oligomers
Laura Pieri et al.
SCIENTIFIC REPORTS (2016)
Nanomechanical properties of distinct fibrillar polymorphs of the protein α-synuclein
Ali Makky et al.
SCIENTIFIC REPORTS (2016)
Mechanism of Anti-alpha-Synuclein Immunotherapy
Jun Sung Lee et al.
JOURNAL OF MOVEMENT DISORDERS (2016)
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations
Benjamin Dehay et al.
LANCET NEUROLOGY (2015)
Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy
Markus Mandler et al.
MOLECULAR NEURODEGENERATION (2015)
α-Synuclein strains cause distinct synucleinopathies after local and systemic administration
W. Peelaerts et al.
NATURE (2015)
Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models
Dora Games et al.
JOURNAL OF NEUROSCIENCE (2014)
Naturally Occurring Alpha-Synuclein Autoantibodies in Parkinson's Disease: Sources of (Error) Variance in Biomarker Assays
Sebastian Heinzel et al.
PLOS ONE (2014)
Antibody-Aided Clearance of Extracellular α-Synuclein Prevents Cell-to-Cell Aggregate Transmission
Eun-Jin Bae et al.
JOURNAL OF NEUROSCIENCE (2012)
Naturally Occurring Autoantibodies against β-Amyloid: Investigating Their Role in Transgenic Animal and In Vitro Models of Alzheimer's Disease
Richard Dodel et al.
JOURNAL OF NEUROSCIENCE (2011)
Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease
Eliezer Masliah et al.
PLOS ONE (2011)
Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease
M. Britschgi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Site-specific UBITh® amyloid-β vaccine for immunotherapy of Alzheimer's disease
Chang Yi Wang et al.
VACCINE (2007)
Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology
H Braak et al.
NEUROSCIENCE LETTERS (2006)
PA700, the regulatory complex of the 26S proteasome, interferes with α-synuclein assembly
M Ghee et al.
FEBS JOURNAL (2005)
Effects of α-synuclein immunization in a mouse model of Parkinson's disease
E Masliah et al.
NEURON (2005)
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
S Gilman et al.
NEUROLOGY (2005)
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide:: a case report
JAR Nicoll et al.
NATURE MEDICINE (2003)
Staging of brain pathology related to sporadic Parkinson's disease
H Braak et al.
NEUROBIOLOGY OF AGING (2003)
Passage of amyloid β protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease
WA Banks et al.
PEPTIDES (2002)
Evidence for a partially folded intermediate in α-synuclein fibril formation
VN Uversky et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
